Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases

Summary

This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.

Timeline

Start

2005-08

Primary completion

2008-04

Completion

—

Drugs

Indications